演題番号 : P43-7
Abiraterone showed survival outcomes in the recent studies. But there are no report about efficacy of abiraterone in castration-resistant prostate cancer (CRPC) patients with IDC-P.
Patients and Method
This retrospective study aimed to apparent efficacy and safety of abiraterone in CRPC patients. We identified 42 patients treated with abiraterone after diagnosis of CRPC from June 2002 to February 2016. All needle biopsy slides were reviewed by a single genitourinary pathologist (TT). We evaluated overall survival from the time of CRPC diagnosis, progression-free survival (PFS) from the administration of aviraterone, prostate-specific antigen (PSA) response and safety. The Cox regression model was used to confirm whether IDC-P would act as independent factors for prognosis.
The median age was 70.5 years (59 to 85), the median serum PSA level before administration of abiraterone was 17.8 ng/ml (0.15 to 2449). The number of patients who had previously been treated with docetaxel was 11. IDC-P was found in 17 of 42 patients. The median OS in the IDC-P present group was 45.0 months versus 92.8 months in the IDC-P absent group (HR, 5.76; 95% CI, 1.68 to 19.7; P = 0.005). The median PFS in patients previously treated with docetaxel was 2.3 months and not treated was 6.3 months, respectively (p=0.65).In patients not previously treated with docetaxel, the median PFS was 6.9 months with IDC-P and 4.6 months without IDC-P, respectively (p=0.09). Treatment-related adverse events occurred in 3 of 42 patients; grade 3 or 4 events occurred in 1 patient. Univariate analysis demonstrated that the presence of IDC-P, initial serum PSA level and the presence of distant metastases at first visit were independent prognostic factors for OS.
The presence of IDC-P would make worse the prognosis of CRPC patients. Regarding PFS, the efficacy of abiraterone may not be affected by the presence of IDC-P.